Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEAR Path 1 pediatric HeFH bempedoic acid PK study
NL-OMON60937Phase 2Completed
- Sponsor
- Esperion Therapeutics
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bempedoic acid in heterozygous familial hypercholesterolemia (HeFH), sponsored by Esperion Therapeutics. Primary endpoints: Observed trough plasma concentration of ETC-1002 after 8 weeks and Model-based steady-state pharmacokinetic parameters of ETC-1002. Started Mar 2023; status: completed.
02
Drugs
bempedoic acid
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NL-OMON60937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60937.